The global HER2-Positive Breast Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.
This report aims to provide a comprehensive presentation of the global market for HER2-Positive Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2-Positive Breast Cancer. This report contains market size and forecasts of HER2-Positive Breast Cancer in global, including the following market information:
- Global HER2-Positive Breast Cancer Market Revenue, 2018-2023, 2024-2032, ($ millions)
- Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Grifola Frondosa Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of HER2-Positive Breast Cancer include Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics and Radius Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the HER2-Positive Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global HER2-Positive Breast Cancer Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global HER2-Positive Breast Cancer Market Segment Percentages, by Type, 2022 (%)
- Grifola Frondosa
- Surgery
- Radiation and Chemotherapy
- Endocrine Therapy
- Molecular Targeted Therapy
Global HER2-Positive Breast Cancer Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global HER2-Positive Breast Cancer Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Specialist Clinic
- Biotechnology and Pharmaceutical Companies
- Research and Academic Institutions
- Other
Global HER2-Positive Breast Cancer Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global HER2-Positive Breast Cancer Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies HER2-Positive Breast Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies HER2-Positive Breast Cancer revenues share in global market, 2022 (%)
key players include:
- Pfizer (Pharmacia and Upjohn Company)
- Novartis
- AstraZeneca Pharmaceuticals
- Eli Lilly
- Roche Group
- Merck
- Jiangsu HengRui Medicine
- Odonate Therapeutics
- Radius Pharmaceuticals
- Immunomedics
- Syndax Pharmaceuticals
- Bayer
- Eagle Pharmaceuticals
- Merrimack Pharmaceuticals
- GlaxoSmithKline
- Millennium Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of HER2-Positive Breast Cancer, market overview.
Chapter 2: Global HER2-Positive Breast Cancer market size in revenue.
Chapter 3: Detailed analysis of HER2-Positive Breast Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments
by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments
by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of HER2-Positive Breast Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 HER2-Positive Breast Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global HER2-Positive Breast Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global HER2-Positive Breast Cancer Overall Market Size
2.1 Global HER2-Positive Breast Cancer Market Size: 2022 VS 2032
2.2 Global HER2-Positive Breast Cancer Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top HER2-Positive Breast Cancer Players in Global Market
3.2 Top Global HER2-Positive Breast Cancer Companies Ranked by Revenue
3.3 Global HER2-Positive Breast Cancer Revenue by Companies
3.4 Top 3 and Top 5 HER2-Positive Breast Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies HER2-Positive Breast Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 HER2-Positive Breast Cancer Players in Global Market
3.6.1 List of Global Tier 1 HER2-Positive Breast Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 HER2-Positive Breast Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global HER2-Positive Breast Cancer Market Size Markets, 2022 & 2032
4.1.2 Grifola Frondosa
4.1.3 Surgery
4.1.4 Radiation and Chemotherapy
4.1.5 Endocrine Therapy
4.1.6 Molecular Targeted Therapy
4.2 By Type - Global HER2-Positive Breast Cancer Revenue & Forecasts
4.2.1 By Type - Global HER2-Positive Breast Cancer Revenue, 2018-2023
4.2.2 By Type - Global HER2-Positive Breast Cancer Revenue, 2024-2032
4.2.3 By Type - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global HER2-Positive Breast Cancer Market Size, 2022 & 2032
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Biotechnology and Pharmaceutical Companies
5.1.5 Research and Academic Institutions
5.1.6 Other
5.2 By Application - Global HER2-Positive Breast Cancer Revenue & Forecasts
5.2.1 By Application - Global HER2-Positive Breast Cancer Revenue, 2018-2023
5.2.2 By Application - Global HER2-Positive Breast Cancer Revenue, 2024-2032
5.2.3 By Application - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global HER2-Positive Breast Cancer Market Size, 2022 & 2032
6.2 By Region - Global HER2-Positive Breast Cancer Revenue & Forecasts
6.2.1 By Region - Global HER2-Positive Breast Cancer Revenue, 2018-2023
6.2.2 By Region - Global HER2-Positive Breast Cancer Revenue, 2024-2032
6.2.3 By Region - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America HER2-Positive Breast Cancer Revenue, 2018-2032
6.3.2 US HER2-Positive Breast Cancer Market Size, 2018-2032
6.3.3 Canada HER2-Positive Breast Cancer Market Size, 2018-2032
6.3.4 Mexico HER2-Positive Breast Cancer Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe HER2-Positive Breast Cancer Revenue, 2018-2032
6.4.2 Germany HER2-Positive Breast Cancer Market Size, 2018-2032
6.4.3 France HER2-Positive Breast Cancer Market Size, 2018-2032
6.4.4 U.K. HER2-Positive Breast Cancer Market Size, 2018-2032
6.4.5 Italy HER2-Positive Breast Cancer Market Size, 2018-2032
6.4.6 Russia HER2-Positive Breast Cancer Market Size, 2018-2032
6.4.7 Nordic Countries HER2-Positive Breast Cancer Market Size, 2018-2032
6.4.8 Benelux HER2-Positive Breast Cancer Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia HER2-Positive Breast Cancer Revenue, 2018-2032
6.5.2 China HER2-Positive Breast Cancer Market Size, 2018-2032
6.5.3 Japan HER2-Positive Breast Cancer Market Size, 2018-2032
6.5.4 South Korea HER2-Positive Breast Cancer Market Size, 2018-2032
6.5.5 Southeast Asia HER2-Positive Breast Cancer Market Size, 2018-2032
6.5.6 India HER2-Positive Breast Cancer Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America HER2-Positive Breast Cancer Revenue, 2018-2032
6.6.2 Brazil HER2-Positive Breast Cancer Market Size, 2018-2032
6.6.3 Argentina HER2-Positive Breast Cancer Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue, 2018-2032
6.7.2 Turkey HER2-Positive Breast Cancer Market Size, 2018-2032
6.7.3 Israel HER2-Positive Breast Cancer Market Size, 2018-2032
6.7.4 Saudi Arabia HER2-Positive Breast Cancer Market Size, 2018-2032
6.7.5 UAE HER2-Positive Breast Cancer Market Size, 2018-2032
7 HER2-Positive Breast Cancer Companies Profiles
7.1 Pfizer (Pharmacia and Upjohn Company)
7.1.1 Pfizer (Pharmacia and Upjohn Company) Company Summary
7.1.2 Pfizer (Pharmacia and Upjohn Company) Business Overview
7.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Major Product Offerings
7.1.4 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.1.5 Pfizer (Pharmacia and Upjohn Company) Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis HER2-Positive Breast Cancer Major Product Offerings
7.2.4 Novartis HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 AstraZeneca Pharmaceuticals
7.3.1 AstraZeneca Pharmaceuticals Company Summary
7.3.2 AstraZeneca Pharmaceuticals Business Overview
7.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
7.3.4 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.3.5 AstraZeneca Pharmaceuticals Key News & Latest Developments
7.4 Eli Lilly
7.4.1 Eli Lilly Company Summary
7.4.2 Eli Lilly Business Overview
7.4.3 Eli Lilly HER2-Positive Breast Cancer Major Product Offerings
7.4.4 Eli Lilly HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.4.5 Eli Lilly Key News & Latest Developments
7.5 Roche Group
7.5.1 Roche Group Company Summary
7.5.2 Roche Group Business Overview
7.5.3 Roche Group HER2-Positive Breast Cancer Major Product Offerings
7.5.4 Roche Group HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.5.5 Roche Group Key News & Latest Developments
7.6 Merck
7.6.1 Merck Company Summary
7.6.2 Merck Business Overview
7.6.3 Merck HER2-Positive Breast Cancer Major Product Offerings
7.6.4 Merck HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.6.5 Merck Key News & Latest Developments
7.7 Jiangsu HengRui Medicine
7.7.1 Jiangsu HengRui Medicine Company Summary
7.7.2 Jiangsu HengRui Medicine Business Overview
7.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Major Product Offerings
7.7.4 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.7.5 Jiangsu HengRui Medicine Key News & Latest Developments
7.8 Odonate Therapeutics
7.8.1 Odonate Therapeutics Company Summary
7.8.2 Odonate Therapeutics Business Overview
7.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Major Product Offerings
7.8.4 Odonate Therapeutics HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.8.5 Odonate Therapeutics Key News & Latest Developments
7.9 Radius Pharmaceuticals
7.9.1 Radius Pharmaceuticals Company Summary
7.9.2 Radius Pharmaceuticals Business Overview
7.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
7.9.4 Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.9.5 Radius Pharmaceuticals Key News & Latest Developments
7.10 Immunomedics
7.10.1 Immunomedics Company Summary
7.10.2 Immunomedics Business Overview
7.10.3 Immunomedics HER2-Positive Breast Cancer Major Product Offerings
7.10.4 Immunomedics HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.10.5 Immunomedics Key News & Latest Developments
7.11 Syndax Pharmaceuticals
7.11.1 Syndax Pharmaceuticals Company Summary
7.11.2 Syndax Pharmaceuticals Business Overview
7.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
7.11.4 Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.11.5 Syndax Pharmaceuticals Key News & Latest Developments
7.12 Bayer
7.12.1 Bayer Company Summary
7.12.2 Bayer Business Overview
7.12.3 Bayer HER2-Positive Breast Cancer Major Product Offerings
7.12.4 Bayer HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.12.5 Bayer Key News & Latest Developments
7.13 Eagle Pharmaceuticals
7.13.1 Eagle Pharmaceuticals Company Summary
7.13.2 Eagle Pharmaceuticals Business Overview
7.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
7.13.4 Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.13.5 Eagle Pharmaceuticals Key News & Latest Developments
7.14 Merrimack Pharmaceuticals
7.14.1 Merrimack Pharmaceuticals Company Summary
7.14.2 Merrimack Pharmaceuticals Business Overview
7.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
7.14.4 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.14.5 Merrimack Pharmaceuticals Key News & Latest Developments
7.15 GlaxoSmithKline
7.15.1 GlaxoSmithKline Company Summary
7.15.2 GlaxoSmithKline Business Overview
7.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Major Product Offerings
7.15.4 GlaxoSmithKline HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.15.5 GlaxoSmithKline Key News & Latest Developments
7.16 Millennium Pharmaceuticals
7.16.1 Millennium Pharmaceuticals Company Summary
7.16.2 Millennium Pharmaceuticals Business Overview
7.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
7.16.4 Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2018-2023)
7.16.5 Millennium Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. HER2-Positive Breast Cancer Market Opportunities & Trends in Global Market
Table 2. HER2-Positive Breast Cancer Market Drivers in Global Market
Table 3. HER2-Positive Breast Cancer Market Restraints in Global Market
Table 4. Key Players of HER2-Positive Breast Cancer in Global Market
Table 5. Top HER2-Positive Breast Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global HER2-Positive Breast Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global HER2-Positive Breast Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies HER2-Positive Breast Cancer Product Type
Table 9. List of Global Tier 1 HER2-Positive Breast Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 HER2-Positive Breast Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global HER2-Positive Breast Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global HER2-Positive Breast Cancer Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe HER2-Positive Breast Cancer Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue, (US$, Mn), 2024-2032
Table 30. Pfizer (Pharmacia and Upjohn Company) Company Summary
Table 31. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Offerings
Table 32. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer (Pharmacia and Upjohn Company) Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis HER2-Positive Breast Cancer Product Offerings
Table 36. Novartis HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. AstraZeneca Pharmaceuticals Company Summary
Table 39. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 40. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. AstraZeneca Pharmaceuticals Key News & Latest Developments
Table 42. Eli Lilly Company Summary
Table 43. Eli Lilly HER2-Positive Breast Cancer Product Offerings
Table 44. Eli Lilly HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Eli Lilly Key News & Latest Developments
Table 46. Roche Group Company Summary
Table 47. Roche Group HER2-Positive Breast Cancer Product Offerings
Table 48. Roche Group HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Roche Group Key News & Latest Developments
Table 50. Merck Company Summary
Table 51. Merck HER2-Positive Breast Cancer Product Offerings
Table 52. Merck HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Merck Key News & Latest Developments
Table 54. Jiangsu HengRui Medicine Company Summary
Table 55. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Offerings
Table 56. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. Jiangsu HengRui Medicine Key News & Latest Developments
Table 58. Odonate Therapeutics Company Summary
Table 59. Odonate Therapeutics HER2-Positive Breast Cancer Product Offerings
Table 60. Odonate Therapeutics HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. Odonate Therapeutics Key News & Latest Developments
Table 62. Radius Pharmaceuticals Company Summary
Table 63. Radius Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 64. Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 65. Radius Pharmaceuticals Key News & Latest Developments
Table 66. Immunomedics Company Summary
Table 67. Immunomedics HER2-Positive Breast Cancer Product Offerings
Table 68. Immunomedics HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 69. Immunomedics Key News & Latest Developments
Table 70. Syndax Pharmaceuticals Company Summary
Table 71. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 72. Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 73. Syndax Pharmaceuticals Key News & Latest Developments
Table 74. Bayer Company Summary
Table 75. Bayer HER2-Positive Breast Cancer Product Offerings
Table 76. Bayer HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 77. Bayer Key News & Latest Developments
Table 78. Eagle Pharmaceuticals Company Summary
Table 79. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 80. Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 81. Eagle Pharmaceuticals Key News & Latest Developments
Table 82. Merrimack Pharmaceuticals Company Summary
Table 83. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 84. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 85. Merrimack Pharmaceuticals Key News & Latest Developments
Table 86. GlaxoSmithKline Company Summary
Table 87. GlaxoSmithKline HER2-Positive Breast Cancer Product Offerings
Table 88. GlaxoSmithKline HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 89. GlaxoSmithKline Key News & Latest Developments
Table 90. Millennium Pharmaceuticals Company Summary
Table 91. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 92. Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 93. Millennium Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. HER2-Positive Breast Cancer Segment by Type in 2022
Figure 2. HER2-Positive Breast Cancer Segment by Application in 2022
Figure 3. Global HER2-Positive Breast Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global HER2-Positive Breast Cancer Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global HER2-Positive Breast Cancer Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by HER2-Positive Breast Cancer Revenue in 2022
Figure 8. By Type - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 9. By Application - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 10. By Type - Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 12. By Application - Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 14. By Region - Global HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 15. By Country - North America HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 16. US HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 17. Canada HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 20. Germany HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 21. France HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 23. Italy HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 24. Russia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 28. China HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 29. Japan HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 32. India HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 34. Brazil HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue Market Share, 2018-2032
Figure 37. Turkey HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 38. Israel HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 40. UAE HER2-Positive Breast Cancer Revenue, (US$, Mn), 2018-2032
Figure 41. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Eli Lilly HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Roche Group HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Merck HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Odonate Therapeutics HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Immunomedics HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Bayer HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. GlaxoSmithKline HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
